These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27018935)

  • 1. Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome: A Review of the Literature Since the 2013 Endocrine Society Clinical Practice Guidelines.
    Fields EL; Trent ME
    JAMA Pediatr; 2016 May; 170(5):502-7. PubMed ID: 27018935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic ovarian syndrome--prognosis and treatment outcomes.
    Hart R
    Curr Opin Obstet Gynecol; 2007 Dec; 19(6):529-35. PubMed ID: 18007129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome.
    Harborne L; Fleming R; Lyall H; Norman J; Sattar N
    Lancet; 2003 May; 361(9372):1894-901. PubMed ID: 12788588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine and metabolic characteristics in polycystic ovary syndrome.
    Glintborg D
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycystic ovary syndrome update in adolescence.
    Hassan A; Gordon CM
    Curr Opin Pediatr; 2007 Aug; 19(4):389-97. PubMed ID: 17630601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of metformin in polycystic ovary syndrome: a meta-analysis.
    Creanga AA; Bradley HM; McCormick C; Witkop CT
    Obstet Gynecol; 2008 Apr; 111(4):959-68. PubMed ID: 18378757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.
    Al Khalifah RA; Flórez ID; Dennis B; Neupane B; Thabane L; Bassilious E
    Syst Rev; 2015 Sep; 4():125. PubMed ID: 26420636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for the metabolic dysfunction in polycystic ovary syndrome.
    Bozdag G; Yildiz BO
    Steroids; 2013 Aug; 78(8):777-81. PubMed ID: 23624033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Insulin sensitizers in the treatment of polycystic ovary].
    Ortiz Núñez DA; Hernández Marín I; Ayala AR
    Ginecol Obstet Mex; 2005 Jun; 73(6):315-27. PubMed ID: 16309038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P; Castello R; Negri C; Tosi F; Perrone F; Caputo M; Zanolin E; Muggeo M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The treatment of polycystic ovary syndrome.
    Ajossa S; Guerriero S; Paoletti AM; Orrù M; Melis GB
    Minerva Ginecol; 2004 Feb; 56(1):15-26. PubMed ID: 14973407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin in polycystic ovary syndrome.
    Diamanti-Kandarakis E; Economou F; Palimeri S; Christakou C
    Ann N Y Acad Sci; 2010 Sep; 1205():192-8. PubMed ID: 20840272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial.
    Orio F; Muscogiuri G; Giallauria F; Savastano S; Bottiglieri P; Tafuri D; Predotti P; Colarieti G; Colao A; Palomba S
    Clin Endocrinol (Oxf); 2016 Nov; 85(5):764-771. PubMed ID: 27219465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular risk in women with polycystic ovary syndrome.
    Cho LW; Atkin SL
    Minerva Endocrinol; 2007 Dec; 32(4):263-73. PubMed ID: 18091663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and Treatment of Polycystic Ovary Syndrome.
    Williams T; Mortada R; Porter S
    Am Fam Physician; 2016 Jul; 94(2):106-13. PubMed ID: 27419327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovarian syndrome--prognosis and outcomes.
    Hart R; Norman R
    Best Pract Res Clin Obstet Gynaecol; 2006 Oct; 20(5):751-78. PubMed ID: 16766228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
    Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients.
    Palomba S; Falbo A; Orio F; Zullo F
    Curr Opin Obstet Gynecol; 2008 Aug; 20(4):364-73. PubMed ID: 18660688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.